Clinical trials: Head and Neck Squamous Cell Carcinomas
Neoplasms, Oral, Mouth Neoplasms
GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
This phase II trial studies how trametinib effects tumor cells in patients with oral cavity squamous cell carcinoma that can be removed by surgery.
- Trial name
- NCT01553851
- Testing
- GSK1120212
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Head and Neck Cancer, Radiation Toxicity
Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Intensity-modulated radiation therapy delivers thin beams of radiation of different strengths directly to the tumor from many angles.
- Conditions
- Head and Neck Cancer, Radiation Toxicity, Xerostomia
- Trial name
- NCT00081029
- Testing
- management of therapy complications, radiation therapy
- Where
- 9 sites in United Kingdom
- Volunteers
- 84 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Colorectal Cancer, High Grade Serous Ovarian Cancer
A Phase I Trial of LY3143921 Hydrate in Solid Tumours
This clinical study looked at a drug called LY3143921 hydrate (a Cdc7 inhibitor) in adult patients with advanced solid tumours. The main aims were to find out the maximum dose of LY3143921 hydrate that could be given safely to…
- Conditions
- Colorectal Cancer, High Grade Serous Ovarian Cancer, Non Small-cell Lung Cancer (Squamous Cell Variant), Urothelial Cancer
- Trial name
- NCT03096054
- Testing
- LY3143921 hydrate
- Where
- 4 sites in United Kingdom
- Volunteers
- 69 people
- Sponsor
- Cancer Research UK
Head and Neck Squamous Cell Carcinoma
Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer
The purpose of this study is to investigate a new agent Axitinib in the treatment of head and neck cancer. This is a new drug that is given as a pill twice a day to treat cancer. This is one of the new, "smart" drugs.
- Trial name
- NCT01469546
- Testing
- Axitinib (AG-013736)
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Michigan Rogel Cancer Center
Head and Neck Cancer
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC
Primary Objective for Phase I 1. To determine the maximally tolerated dose (MTD) of daily Oral dasatinib in combination with cetuximab/RT in Cohort A. 2.
- Trial name
- Dasatinib (NCT00882583)
- Testing
- Cetuximab, Dasatinib, Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma
Stereotactic Body Radiotherapy for Head and Neck Tumors
This study will evaluate the local control rates as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of benign and malignant head and neck tumors.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Salivary Gland Cancer, Head and Neck Sarcoma
- Trial name
- NCT01344356
- Testing
- stereotactic body radiotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mercy Research
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- APOLLO (NCT07909031)
- Testing
- CR-002
- Where
- 3 sites in United States
- Volunteers
- 219 people
- Sponsor
- Crescent Biopharma, Inc.
Esophageal Squamous Cell Carcinoma
Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer
This study is an open-label, biomarker-integrated umbrella trial designed to evaluate the clinical efficacy of molecular subtype- and genomic biomarker-guided precision therapies in patients with advanced esophageal cancer…
- Trial name
- ESCC-PT (NCT07653451)
- Testing
- Afatinib + Toripalimab, Dalpiciclib + Pyrotinib, Camrelizumab + Apatinib
- Volunteers
- 90 people
- Sponsor
- Peking University Cancer Hospital & Institute
Squamous Cell Carcinoma of Head and Neck
A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT04183166
- Testing
- TG4050
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Transgene
Head and Neck Squamous Cell Carcinoma
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
This is a multi-center, open-label, Phase 0 substudy designed to evaluate the localized pharmacodynamics (PD) of rilvegostomig, volrustomig, sabestomig, and AZD9592 within the tumor microenvironment (TME) when administered…
- Trial name
- NCT06366451
- Testing
- Rilvegostomig, Volrustomig, Sabestomig
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Presage Biosciences
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer
COMPORT is a multicenter phase II clinical trial evaluating a personalized approach to postoperative radiotherapy in patients with head and neck squamous cell carcinoma (HNSCC).
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- COMPORT (NCT07058805)
- Testing
- Compartmentalized Postoperative Radiotherapy
- Where
- 3 sites in Switzerland
- Volunteers
- 50 people
- Sponsor
- Olgun Elicin
Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer
Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer
This study aims to evaluate whether reducing the intensity of radiotherapy (de-escalated radiotherapy) after induction chemoimmunotherapy is not inferior to standard-dose radiotherapy in patients with locally advanced head and…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer, HNSCC
- Trial name
- IDEAL-RT (NCT07791602)
- Testing
- Camrelizumab, Platinum-based Chemotherapy plus PD-1 inhibitor, De-escalated Radiotherapy
- Where
- 6 sites in China
- Volunteers
- 180 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Squamous Cell Carcinoma
A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)
To evaluate the efficacy and safety of camrelizumab combined with albumin paclitaxel and platinum chemotherapy in the preoperative treatment of locally advanced thoracic esophageal squamous cell carcinoma
- Trial name
- NCT04767295
- Testing
- Camrelizumab, Albumin Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Hunan Cancer Hospital
ESCC, Gastric Adenocarcinoma
Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
This is a single-arm, multi-center phase II study to evaluate the efficacy and safety of sacituzumab tirumotecan (Sac-TMT/SKB264) combined with tagitanlimab (KL-A167) as 2nd line therapy for recurrent or metastatic esophageal…
- Conditions
- ESCC, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- NCT07701681
- Testing
- Sacituzumab Tirumotecan + Tagitanlimab
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Sun Yat-sen University
Squamous Cell Carcinoma of Head and Neck
A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This is a single-arm, open-label, phase II study to evaluate the efficacy and safety of the combination of the antibodies iparomlimab and tuvonralimab, administered with or without chemotherapy, in patients with recurrent or…
- Trial name
- NCT07546383
- Testing
- Iparomlimab and tuvonralimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- The Second Affiliated Hospital of Hainan Medical University
Cancer, Head and Neck Squamous Cell Carcinoma
Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell Carcinoma
This research study will include patients with high risk locally advanced head and neck squamous cell carcinoma (LA-HNSCC) of the oral cavity, oropharynx, hypopharynx or larynx and patients that are starting on standard…
- Conditions
- Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT04599309
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- University Health Network, Toronto
Esophageal Squamous Cell Carcinoma
Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer
This study used an open single center study design to observe the efficacy and safety of Penpulimab combined with Chemoradiotherapy(CRT) in preoperative T2,3,4aN0-1-2M0 esophageal squamous cell carcinoma (ESCC).
- Trial name
- SPEED (NCT05561699)
- Testing
- Penpulimab Combined With CRT
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Shanghai Zhongshan Hospital
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
This study is a single-arm Phase II trial designed to evaluate the efficacy and safety of Docetaxel, Nimotuzumab, and Pucotenlimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma…
- Trial name
- PIONEER-HN (NCT07354984)
- Testing
- Drug Combination Therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
HPV, Oropharyngeal Squamous Cell Carcinoma
Post-treatment Surveillance in HPV+ Oropharyngeal SCC
In this research study the investigators are examining a blood test to detect HPV DNA in the blood that can possibly detect cancer recurrence earlier than with standard surveillance measures.
- Trial name
- NCT04965792
- Testing
- Screening
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Dana-Farber Cancer Institute
Head and Neck Squamous Cell Carcinoma
The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
This is a phase 2, single-arm clinical trial, with the purpose to evaluate the therapeutic efficacy and safety of PD-1 Blockade camrelizumab combined with induction chemotherapy followed by concurrent chemoradiotherapy and as…
- Trial name
- NCT05213884
- Testing
- Camrelizumab, Concurrent cisplatin chemotherapy, Intensity-modulated radiotherapy (IMRT)
- Where
- 3 sites in China
- Volunteers
- 39 people
- Sponsor
- Chongqing University Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.